HomeCompareNMTR vs O

NMTR vs O: Dividend Comparison 2026

NMTR yields 2770.08% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NMTR wins by $212938372920.87M in total portfolio value
10 years
NMTR
NMTR
● Live price
2770.08%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$212938372920.91M
Annual income
$198,819,380,806,317,020.00
Full NMTR calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — NMTR vs O

📍 NMTR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNMTRO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NMTR + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NMTR pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NMTR
Annual income on $10K today (after 15% tax)
$235,457.06/yr
After 10yr DRIP, annual income (after tax)
$168,996,473,685,369,470.00/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, NMTR beats the other by $168,996,473,685,365,120.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NMTR + O for your $10,000?

NMTR: 50%O: 50%
100% O50/50100% NMTR
Portfolio after 10yr
$106469186460.47M
Annual income
$99,409,690,403,161,060.00/yr
Blended yield
93.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

NMTR
No analyst data
Altman Z
-49.9
Piotroski
2/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NMTR buys
0
O buys
0
No recent congressional trades found for NMTR or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNMTRO
Forward yield2770.08%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$212938372920.91M$34.2K
Annual income after 10y$198,819,380,806,317,020.00$5,102.74
Total dividends collected$211957883813.74M$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: NMTR vs O ($10,000, DRIP)

YearNMTR PortfolioNMTR Income/yrO PortfolioO Income/yrGap
1← crossover$287,708$277,008.31$10,818$608.16+$276.9KNMTR
2$7,756,221$7,448,373.17$11,787$741.68+$7.74MNMTR
3$195,960,759$187,661,602.67$12,946$911.00+$195.95MNMTR
4$4,640,768,087$4,431,090,074.46$14,345$1,127.94+$4640.75MNMTR
5$103,038,191,206$98,072,569,353.09$16,056$1,409.05+$103038.18MNMTR
6$2,145,287,049,877$2,035,036,185,286.86$18,171$1,777.83+$2145287.03MNMTR
7$41,893,666,105,695$39,598,208,962,326.13$20,820$2,268.21+$41893666.08MNMTR
8$767,520,675,750,287$722,694,453,017,193.00$24,188$2,929.90+$767520675.73MNMTR
9$13,195,319,733,262,706$12,374,072,610,209,900.00$28,533$3,837.11+$13195319733.23MNMTR
10$212,938,372,920,908,130$198,819,380,806,317,020.00$34,235$5,102.74+$212938372920.87MNMTR

NMTR vs O: Complete Analysis 2026

NMTRStock

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.

Full NMTR Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this NMTR vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NMTR vs SCHDNMTR vs JEPINMTR vs KONMTR vs MAINNMTR vs STAGNMTR vs ADCNMTR vs NNNNMTR vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.